Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/26/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS

6. NVDA
7. AWK
8. DRI
9. ULS
10. CRL

Get Alerts KZR Hot Sheet

Price: $7.29 --0%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in two upcoming investor conferences taking place in September:

Event: 2025 Wells Fargo Healthcare Conference
Location: Boston, MA
Date/Time: Friday, September 5, 2025, at 11:00 am ET
Format: Fireside Chat

Event: H.C. Wainwright 27th Annual Global Investment Conference
Location: New York, NY
Date/Time: Monday, September 8, 2025, at 7:00 am ET
Format: Pre-Recorded On-Demand Presentation

A webcast of the fireside chat at the 2025 Wells Fargo Healthcare Conference will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.